Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in TP53 Mutated Relapsed/Refractory AML
NCT03063203Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2017
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML), sponsored by Washington University School of Medicine. Started Jul 2017; status: terminated.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03063203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063203.